Article
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.
Scientific reports - 16 Dec 2015
Takai Erina, Totoki Yasushi, Nakamura Hiromi, Morizane Chigusa, Nara Satoshi, Hama Natsuko, Suzuki Masami, Furukawa Eisaku, Kato Mamoru, Hayashi Hideyuki, Kohno Takashi, Ueno Hideki, Shimada Kazuaki, Okusaka Takuji, Nakagama Hitoshi, Shibata Tatsuhiro, Yachida Shinichi
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. The genomic landscape of the PDAC genome features four frequently mutated genes (KRAS, CDKN2A, TP53, and SMAD4) and dozens of candidate driver genes altered at low frequency, including potential clinical targets. Circulating cell-free DNA (cfDNA) is a promising resource to detect and monitor molecular characteristics of tumors....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.